Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurology | 16 | 2023 | 49 | 7.180 |
Why?
|
Students, Medical | 13 | 2023 | 131 | 5.580 |
Why?
|
Brain Neoplasms | 26 | 2022 | 638 | 5.000 |
Why?
|
Glioma | 12 | 2022 | 136 | 4.210 |
Why?
|
Internship and Residency | 10 | 2022 | 306 | 3.420 |
Why?
|
Education, Medical | 5 | 2018 | 70 | 2.500 |
Why?
|
Humans | 99 | 2023 | 32297 | 2.360 |
Why?
|
Glioblastoma | 7 | 2020 | 157 | 2.210 |
Why?
|
Antineoplastic Agents | 5 | 2022 | 611 | 1.920 |
Why?
|
Central Nervous System Neoplasms | 4 | 2015 | 29 | 1.900 |
Why?
|
Fellowships and Scholarships | 3 | 2018 | 53 | 1.770 |
Why?
|
Radial Neuropathy | 2 | 2023 | 11 | 1.720 |
Why?
|
Meningeal Neoplasms | 4 | 2022 | 49 | 1.710 |
Why?
|
Brain | 5 | 2021 | 971 | 1.550 |
Why?
|
Physician-Patient Relations | 4 | 2020 | 188 | 1.530 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2022 | 370 | 1.440 |
Why?
|
Astrocytoma | 4 | 2021 | 29 | 1.430 |
Why?
|
Neurofibromatosis 1 | 3 | 2019 | 9 | 1.380 |
Why?
|
Nervous System Diseases | 4 | 2018 | 42 | 1.370 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 46 | 1.350 |
Why?
|
Curriculum | 6 | 2023 | 210 | 1.320 |
Why?
|
Tuberous Sclerosis | 2 | 2019 | 8 | 1.240 |
Why?
|
Immunotherapy | 3 | 2018 | 83 | 1.220 |
Why?
|
Pituitary Neoplasms | 2 | 2017 | 19 | 1.110 |
Why?
|
Neoplasms | 3 | 2023 | 695 | 1.090 |
Why?
|
Adenoma | 2 | 2017 | 39 | 1.090 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2018 | 40 | 1.080 |
Why?
|
Dacarbazine | 3 | 2016 | 29 | 1.070 |
Why?
|
Female | 37 | 2023 | 20126 | 1.050 |
Why?
|
Clinical Competence | 5 | 2018 | 331 | 0.980 |
Why?
|
Communication | 5 | 2021 | 140 | 0.960 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 462 | 0.930 |
Why?
|
Mentors | 2 | 2013 | 31 | 0.910 |
Why?
|
Stroke | 3 | 2020 | 585 | 0.900 |
Why?
|
Sulfones | 2 | 2020 | 21 | 0.900 |
Why?
|
Clinical Clerkship | 1 | 2023 | 42 | 0.900 |
Why?
|
von Hippel-Lindau Disease | 1 | 2023 | 5 | 0.900 |
Why?
|
Indans | 2 | 2020 | 31 | 0.890 |
Why?
|
Electronic Health Records | 2 | 2015 | 158 | 0.880 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2022 | 51 | 0.880 |
Why?
|
Deep Brain Stimulation | 2 | 2015 | 49 | 0.860 |
Why?
|
Male | 29 | 2021 | 19488 | 0.840 |
Why?
|
Middle Aged | 23 | 2021 | 11949 | 0.800 |
Why?
|
Meningeal Carcinomatosis | 1 | 2021 | 7 | 0.790 |
Why?
|
Meningioma | 2 | 2022 | 57 | 0.790 |
Why?
|
Buprenorphine | 1 | 2021 | 18 | 0.780 |
Why?
|
Medical Oncology | 2 | 2021 | 84 | 0.770 |
Why?
|
Students, Health Occupations | 1 | 2020 | 8 | 0.750 |
Why?
|
Telemedicine | 1 | 2022 | 99 | 0.750 |
Why?
|
Education, Pharmacy | 1 | 2020 | 13 | 0.750 |
Why?
|
Aged | 18 | 2023 | 10398 | 0.740 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 56 | 0.740 |
Why?
|
Neurosciences | 2 | 2019 | 11 | 0.720 |
Why?
|
Tibial Nerve | 1 | 2020 | 22 | 0.710 |
Why?
|
Movement Disorders | 2 | 2010 | 25 | 0.710 |
Why?
|
Ketone Bodies | 1 | 2019 | 9 | 0.710 |
Why?
|
Sural Nerve | 1 | 2020 | 28 | 0.700 |
Why?
|
Taxoids | 1 | 2020 | 59 | 0.700 |
Why?
|
Physicians | 2 | 2019 | 161 | 0.690 |
Why?
|
Median Nerve | 1 | 2020 | 51 | 0.690 |
Why?
|
Faculty, Medical | 2 | 2017 | 78 | 0.690 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 82 | 0.690 |
Why?
|
Breast Neoplasms | 4 | 2020 | 759 | 0.670 |
Why?
|
Learning | 2 | 2019 | 79 | 0.660 |
Why?
|
Adult | 17 | 2022 | 9467 | 0.630 |
Why?
|
Retrospective Studies | 13 | 2022 | 3514 | 0.630 |
Why?
|
Neurilemmoma | 1 | 2017 | 16 | 0.620 |
Why?
|
Wrist | 3 | 2023 | 48 | 0.600 |
Why?
|
Skin | 1 | 2019 | 217 | 0.600 |
Why?
|
Lung Neoplasms | 1 | 2021 | 409 | 0.590 |
Why?
|
Ultrasonography | 1 | 2020 | 398 | 0.580 |
Why?
|
Weight Gain | 2 | 2015 | 114 | 0.580 |
Why?
|
Parkinson Disease | 2 | 2015 | 69 | 0.580 |
Why?
|
Truth Disclosure | 1 | 2016 | 13 | 0.580 |
Why?
|
Neuromuscular Agents | 1 | 2017 | 28 | 0.570 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 316 | 0.570 |
Why?
|
Neoplasms, Nerve Tissue | 1 | 2016 | 2 | 0.550 |
Why?
|
Dietary Supplements | 2 | 2015 | 184 | 0.550 |
Why?
|
Paraneoplastic Syndromes | 1 | 2016 | 5 | 0.550 |
Why?
|
Subthalamic Nucleus | 1 | 2015 | 13 | 0.530 |
Why?
|
Personal Satisfaction | 1 | 2015 | 28 | 0.530 |
Why?
|
Central Nervous System Diseases | 1 | 2015 | 13 | 0.530 |
Why?
|
Goals | 1 | 2015 | 37 | 0.530 |
Why?
|
Prospective Studies | 5 | 2023 | 2274 | 0.520 |
Why?
|
Germinoma | 1 | 2015 | 2 | 0.510 |
Why?
|
Tremor | 1 | 2015 | 11 | 0.510 |
Why?
|
Prolactinoma | 1 | 2015 | 2 | 0.510 |
Why?
|
Brain Stem | 1 | 2015 | 21 | 0.510 |
Why?
|
Lymphoma | 1 | 2015 | 35 | 0.500 |
Why?
|
Hemianopsia | 1 | 2014 | 6 | 0.480 |
Why?
|
Glucose | 1 | 2015 | 177 | 0.480 |
Why?
|
Case-Control Studies | 5 | 2017 | 911 | 0.470 |
Why?
|
Epilepsy, Tonic-Clonic | 1 | 2013 | 9 | 0.460 |
Why?
|
Postural Balance | 1 | 2016 | 180 | 0.460 |
Why?
|
Pseudolymphoma | 1 | 2013 | 4 | 0.460 |
Why?
|
Hyperglycemia | 1 | 2014 | 84 | 0.460 |
Why?
|
Glucocorticoids | 1 | 2015 | 161 | 0.450 |
Why?
|
Teaching | 2 | 2014 | 62 | 0.450 |
Why?
|
Pesticides | 1 | 2016 | 202 | 0.440 |
Why?
|
Patient Readmission | 1 | 2014 | 115 | 0.440 |
Why?
|
Influenza Vaccines | 1 | 2014 | 79 | 0.440 |
Why?
|
Semen | 1 | 2013 | 13 | 0.440 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2012 | 6 | 0.440 |
Why?
|
Sperm Motility | 1 | 2013 | 12 | 0.440 |
Why?
|
Occupational Exposure | 1 | 2016 | 238 | 0.440 |
Why?
|
Prognosis | 8 | 2023 | 1523 | 0.430 |
Why?
|
Paresis | 1 | 2012 | 11 | 0.430 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 8 | 0.430 |
Why?
|
Functional Laterality | 1 | 2012 | 57 | 0.430 |
Why?
|
Transients and Migrants | 1 | 2016 | 293 | 0.430 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 250 | 0.420 |
Why?
|
Treatment Outcome | 11 | 2022 | 3358 | 0.420 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 28 | 0.420 |
Why?
|
Horner Syndrome | 1 | 2012 | 1 | 0.420 |
Why?
|
Spider Venoms | 1 | 2012 | 3 | 0.420 |
Why?
|
Educational Measurement | 2 | 2010 | 119 | 0.420 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 45 | 0.420 |
Why?
|
Schools, Medical | 3 | 2019 | 46 | 0.410 |
Why?
|
Education, Medical, Undergraduate | 4 | 2021 | 88 | 0.410 |
Why?
|
Follow-Up Studies | 8 | 2022 | 2296 | 0.410 |
Why?
|
Spinal Diseases | 1 | 2012 | 16 | 0.410 |
Why?
|
Arteriovenous Fistula | 1 | 2012 | 18 | 0.410 |
Why?
|
Steroids | 1 | 2012 | 38 | 0.400 |
Why?
|
Comprehensive Health Care | 1 | 2011 | 5 | 0.380 |
Why?
|
Interinstitutional Relations | 1 | 2011 | 12 | 0.380 |
Why?
|
Anti-Inflammatory Agents | 1 | 2012 | 102 | 0.380 |
Why?
|
Community Health Centers | 1 | 2011 | 15 | 0.380 |
Why?
|
Esophagus | 1 | 2010 | 22 | 0.370 |
Why?
|
Hematoma | 1 | 2010 | 26 | 0.370 |
Why?
|
Quality of Life | 3 | 2019 | 915 | 0.370 |
Why?
|
Ambulatory Care Facilities | 1 | 2011 | 83 | 0.370 |
Why?
|
Pseudobulbar Palsy | 1 | 2010 | 5 | 0.360 |
Why?
|
Mood Disorders | 1 | 2010 | 20 | 0.360 |
Why?
|
Pilot Projects | 3 | 2020 | 536 | 0.360 |
Why?
|
Cross-Sectional Studies | 3 | 2020 | 1522 | 0.350 |
Why?
|
Hispanic Americans | 1 | 2016 | 949 | 0.340 |
Why?
|
Electrodiagnosis | 2 | 2020 | 42 | 0.320 |
Why?
|
Anxiety | 1 | 2010 | 185 | 0.320 |
Why?
|
Radiotherapy | 2 | 2019 | 82 | 0.320 |
Why?
|
Survival Rate | 5 | 2018 | 894 | 0.310 |
Why?
|
Neural Conduction | 2 | 2020 | 91 | 0.310 |
Why?
|
Chest Pain | 1 | 2010 | 197 | 0.310 |
Why?
|
Patient Care Team | 2 | 2020 | 131 | 0.280 |
Why?
|
Combined Modality Therapy | 4 | 2018 | 567 | 0.280 |
Why?
|
Weight Loss | 1 | 2010 | 454 | 0.280 |
Why?
|
Cohort Studies | 3 | 2020 | 1832 | 0.280 |
Why?
|
Radiosurgery | 2 | 2022 | 356 | 0.280 |
Why?
|
Magnetic Resonance Imaging | 7 | 2021 | 1345 | 0.270 |
Why?
|
Diagnosis, Differential | 4 | 2018 | 525 | 0.260 |
Why?
|
Neurologic Examination | 2 | 2017 | 28 | 0.250 |
Why?
|
Electromyography | 2 | 2017 | 61 | 0.240 |
Why?
|
Educational Status | 2 | 2022 | 177 | 0.240 |
Why?
|
Genomics | 3 | 2021 | 85 | 0.240 |
Why?
|
Aged, 80 and over | 6 | 2018 | 4050 | 0.230 |
Why?
|
Cell Line, Tumor | 3 | 2020 | 736 | 0.230 |
Why?
|
Consensus | 2 | 2021 | 83 | 0.230 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 119 | 0.230 |
Why?
|
Problem-Based Learning | 1 | 2023 | 29 | 0.230 |
Why?
|
Animals | 6 | 2022 | 7694 | 0.230 |
Why?
|
Paclitaxel | 2 | 2022 | 67 | 0.230 |
Why?
|
Quality of Health Care | 2 | 2017 | 151 | 0.220 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2023 | 16 | 0.220 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 16 | 0.220 |
Why?
|
Hypesthesia | 1 | 2022 | 10 | 0.210 |
Why?
|
Mice | 4 | 2022 | 2524 | 0.210 |
Why?
|
Elbow | 1 | 2022 | 26 | 0.210 |
Why?
|
Neoplastic Stem Cells | 2 | 2020 | 99 | 0.210 |
Why?
|
Oligodendroglioma | 1 | 2021 | 2 | 0.210 |
Why?
|
Ketosis | 1 | 2021 | 1 | 0.200 |
Why?
|
Prevalence | 2 | 2018 | 986 | 0.200 |
Why?
|
Health Occupations | 1 | 2020 | 1 | 0.190 |
Why?
|
Fasting | 1 | 2021 | 97 | 0.190 |
Why?
|
Janus Kinase 2 | 1 | 2020 | 6 | 0.190 |
Why?
|
Societies | 1 | 2020 | 5 | 0.190 |
Why?
|
Patient Simulation | 1 | 2020 | 32 | 0.190 |
Why?
|
Interprofessional Relations | 1 | 2020 | 51 | 0.180 |
Why?
|
Feasibility Studies | 1 | 2021 | 294 | 0.180 |
Why?
|
Disease Progression | 3 | 2018 | 618 | 0.180 |
Why?
|
Delivery of Health Care | 1 | 2022 | 161 | 0.180 |
Why?
|
Ankle | 1 | 2020 | 29 | 0.180 |
Why?
|
Epidermis | 1 | 2020 | 30 | 0.180 |
Why?
|
Albumins | 1 | 2020 | 46 | 0.180 |
Why?
|
Forearm | 1 | 2020 | 43 | 0.180 |
Why?
|
Nerve Fibers | 1 | 2020 | 37 | 0.180 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2019 | 3 | 0.180 |
Why?
|
Neurocutaneous Syndromes | 1 | 2019 | 4 | 0.180 |
Why?
|
Leg | 1 | 2020 | 66 | 0.180 |
Why?
|
Mice, Nude | 1 | 2020 | 298 | 0.170 |
Why?
|
Cell Movement | 1 | 2020 | 171 | 0.170 |
Why?
|
Meninges | 1 | 2019 | 1 | 0.170 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 1 | 2019 | 6 | 0.170 |
Why?
|
Serial Publications | 1 | 2018 | 3 | 0.160 |
Why?
|
Peer Group | 1 | 2019 | 44 | 0.160 |
Why?
|
Immunologic Factors | 1 | 2019 | 49 | 0.160 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 13 | 0.160 |
Why?
|
Gangrene | 1 | 2018 | 4 | 0.160 |
Why?
|
Paraplegia | 1 | 2018 | 6 | 0.160 |
Why?
|
Vasculitis, Central Nervous System | 1 | 2018 | 5 | 0.160 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 262 | 0.160 |
Why?
|
Biopsy | 2 | 2017 | 273 | 0.160 |
Why?
|
RNA Interference | 1 | 2018 | 77 | 0.160 |
Why?
|
Transcription Factors | 1 | 2019 | 181 | 0.160 |
Why?
|
Foot | 1 | 2018 | 40 | 0.160 |
Why?
|
Diagnostic Techniques, Endocrine | 1 | 2017 | 1 | 0.160 |
Why?
|
Neoplasm Staging | 2 | 2018 | 459 | 0.160 |
Why?
|
Societies, Scientific | 1 | 2018 | 15 | 0.150 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 117 | 0.150 |
Why?
|
Cell Proliferation | 1 | 2020 | 602 | 0.150 |
Why?
|
Congresses as Topic | 1 | 2018 | 39 | 0.150 |
Why?
|
Leukocyte Count | 1 | 2017 | 64 | 0.150 |
Why?
|
Professional-Patient Relations | 1 | 2018 | 26 | 0.150 |
Why?
|
Time Management | 1 | 2017 | 9 | 0.150 |
Why?
|
Headache | 1 | 2018 | 78 | 0.150 |
Why?
|
Young Adult | 4 | 2018 | 2626 | 0.150 |
Why?
|
Absorptiometry, Photon | 1 | 2017 | 133 | 0.150 |
Why?
|
Focus Groups | 1 | 2018 | 111 | 0.150 |
Why?
|
Hospice Care | 1 | 2017 | 13 | 0.150 |
Why?
|
Terminal Care | 1 | 2017 | 24 | 0.150 |
Why?
|
Iatrogenic Disease | 1 | 2017 | 17 | 0.150 |
Why?
|
Osteoporosis | 1 | 2017 | 57 | 0.150 |
Why?
|
Hypoglycemic Agents | 1 | 2018 | 188 | 0.150 |
Why?
|
Qualitative Research | 1 | 2018 | 159 | 0.140 |
Why?
|
Muscle Weakness | 1 | 2017 | 39 | 0.140 |
Why?
|
Mental Disorders | 1 | 2018 | 119 | 0.140 |
Why?
|
Guideline Adherence | 1 | 2017 | 122 | 0.140 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 126 | 0.140 |
Why?
|
Head | 1 | 2017 | 49 | 0.140 |
Why?
|
Epilepsy | 1 | 2017 | 82 | 0.140 |
Why?
|
Signal Transduction | 1 | 2020 | 701 | 0.140 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 77 | 0.140 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 154 | 0.140 |
Why?
|
Lumbosacral Plexus | 1 | 2016 | 5 | 0.140 |
Why?
|
Neurofibromatosis 2 | 1 | 2016 | 5 | 0.140 |
Why?
|
Bone Density | 1 | 2017 | 186 | 0.140 |
Why?
|
Lomustine | 1 | 2016 | 2 | 0.140 |
Why?
|
Procarbazine | 1 | 2016 | 5 | 0.140 |
Why?
|
Carmustine | 1 | 2016 | 8 | 0.140 |
Why?
|
Vincristine | 1 | 2016 | 18 | 0.140 |
Why?
|
Dermatomyositis | 1 | 2016 | 19 | 0.130 |
Why?
|
beta Catenin | 1 | 2016 | 37 | 0.130 |
Why?
|
Publications | 1 | 2015 | 9 | 0.130 |
Why?
|
Time Factors | 3 | 2021 | 2181 | 0.130 |
Why?
|
Metabolic Networks and Pathways | 1 | 2015 | 20 | 0.130 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 93 | 0.130 |
Why?
|
Methylprednisolone | 1 | 2015 | 13 | 0.130 |
Why?
|
Prolactin | 1 | 2015 | 12 | 0.130 |
Why?
|
Retreatment | 1 | 2015 | 42 | 0.130 |
Why?
|
Linear Models | 1 | 2015 | 454 | 0.120 |
Why?
|
Intracranial Hemorrhages | 1 | 2014 | 33 | 0.120 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2014 | 23 | 0.120 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 410 | 0.120 |
Why?
|
Influenza B virus | 1 | 2014 | 20 | 0.120 |
Why?
|
Physician's Role | 1 | 2014 | 41 | 0.120 |
Why?
|
Documentation | 1 | 2014 | 45 | 0.120 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 379 | 0.120 |
Why?
|
Energy Metabolism | 1 | 2015 | 147 | 0.120 |
Why?
|
Phenotype | 1 | 2016 | 656 | 0.120 |
Why?
|
Biological Products | 1 | 2015 | 78 | 0.120 |
Why?
|
Hyperlipidemias | 1 | 2014 | 54 | 0.120 |
Why?
|
Sex Factors | 1 | 2015 | 674 | 0.110 |
Why?
|
Risk Factors | 1 | 2022 | 3876 | 0.110 |
Why?
|
Adolescent | 4 | 2018 | 3571 | 0.110 |
Why?
|
Pipecolic Acids | 1 | 2012 | 6 | 0.110 |
Why?
|
Hirudins | 1 | 2012 | 19 | 0.110 |
Why?
|
Polysaccharides | 1 | 2012 | 13 | 0.110 |
Why?
|
Vena Cava Filters | 1 | 2012 | 13 | 0.110 |
Why?
|
Thrombocytopenia | 1 | 2012 | 32 | 0.110 |
Why?
|
Electroencephalography | 3 | 2022 | 73 | 0.110 |
Why?
|
Gonadal Steroid Hormones | 1 | 2013 | 29 | 0.110 |
Why?
|
Diet | 1 | 2015 | 384 | 0.110 |
Why?
|
Warfarin | 1 | 2012 | 32 | 0.110 |
Why?
|
Brain Ischemia | 1 | 2014 | 146 | 0.110 |
Why?
|
Blood Glucose | 1 | 2015 | 496 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2012 | 50 | 0.110 |
Why?
|
Black Widow Spider | 1 | 2012 | 1 | 0.110 |
Why?
|
Paraparesis | 1 | 2012 | 3 | 0.100 |
Why?
|
Seafood | 1 | 2012 | 11 | 0.100 |
Why?
|
Recombinant Proteins | 1 | 2012 | 258 | 0.100 |
Why?
|
Food Hypersensitivity | 1 | 2012 | 8 | 0.100 |
Why?
|
Dura Mater | 1 | 2012 | 14 | 0.100 |
Why?
|
Hemorrhage | 1 | 2012 | 101 | 0.100 |
Why?
|
Anaphylaxis | 1 | 2012 | 12 | 0.100 |
Why?
|
Prednisone | 1 | 2012 | 62 | 0.100 |
Why?
|
Angiography | 1 | 2012 | 80 | 0.100 |
Why?
|
Anticoagulants | 1 | 2012 | 127 | 0.100 |
Why?
|
North Carolina | 1 | 2016 | 1520 | 0.100 |
Why?
|
Vascular Surgical Procedures | 1 | 2012 | 92 | 0.100 |
Why?
|
Alendronate | 1 | 2010 | 12 | 0.090 |
Why?
|
Bone Density Conservation Agents | 1 | 2010 | 21 | 0.090 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 492 | 0.090 |
Why?
|
Severity of Illness Index | 1 | 2014 | 926 | 0.090 |
Why?
|
Emaciation | 1 | 2010 | 4 | 0.090 |
Why?
|
Licensure, Medical | 1 | 2010 | 3 | 0.090 |
Why?
|
Essential Tremor | 1 | 2010 | 12 | 0.090 |
Why?
|
Acute Disease | 1 | 2010 | 255 | 0.090 |
Why?
|
Antidepressive Agents | 1 | 2010 | 77 | 0.090 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 65 | 0.090 |
Why?
|
Depressive Disorder | 1 | 2010 | 76 | 0.090 |
Why?
|
Health Surveys | 1 | 2010 | 202 | 0.090 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2009 | 7 | 0.090 |
Why?
|
Chronic Disease | 1 | 2011 | 406 | 0.080 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 172 | 0.080 |
Why?
|
Spinal Nerves | 1 | 2009 | 66 | 0.080 |
Why?
|
Comorbidity | 1 | 2010 | 572 | 0.080 |
Why?
|
Postoperative Complications | 1 | 2012 | 788 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 877 | 0.070 |
Why?
|
Decision Making | 1 | 2009 | 205 | 0.070 |
Why?
|
Disease Management | 2 | 2018 | 131 | 0.070 |
Why?
|
Sensation | 1 | 2006 | 55 | 0.070 |
Why?
|
Attention | 1 | 2006 | 83 | 0.070 |
Why?
|
Germinal Center | 1 | 2023 | 5 | 0.060 |
Why?
|
Immersion | 1 | 2022 | 3 | 0.050 |
Why?
|
Competency-Based Education | 1 | 2022 | 6 | 0.050 |
Why?
|
Gelatin | 1 | 2022 | 29 | 0.050 |
Why?
|
Central Nervous System | 1 | 2023 | 46 | 0.050 |
Why?
|
Hyaluronic Acid | 1 | 2022 | 49 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 79 | 0.050 |
Why?
|
Hydrogels | 1 | 2022 | 122 | 0.050 |
Why?
|
Organoids | 1 | 2022 | 94 | 0.050 |
Why?
|
Collagen | 1 | 2022 | 228 | 0.050 |
Why?
|
Hyperalgesia | 1 | 2022 | 88 | 0.050 |
Why?
|
Seizures | 1 | 2021 | 70 | 0.050 |
Why?
|
Intention | 1 | 2021 | 28 | 0.050 |
Why?
|
Attitude | 1 | 2021 | 41 | 0.050 |
Why?
|
Neurosurgical Procedures | 1 | 2021 | 100 | 0.050 |
Why?
|
Anilides | 1 | 2020 | 10 | 0.050 |
Why?
|
Biphenyl Compounds | 1 | 2020 | 19 | 0.050 |
Why?
|
Alternative Splicing | 1 | 2020 | 30 | 0.050 |
Why?
|
STAT3 Transcription Factor | 1 | 2020 | 26 | 0.050 |
Why?
|
Drug Synergism | 1 | 2020 | 71 | 0.050 |
Why?
|
Minority Groups | 1 | 2021 | 76 | 0.050 |
Why?
|
Cerebral Cortex | 1 | 2021 | 137 | 0.050 |
Why?
|
Pyridines | 1 | 2020 | 81 | 0.050 |
Why?
|
Pyrazoles | 1 | 2020 | 68 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 217 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 85 | 0.040 |
Why?
|
Pyrimidines | 1 | 2020 | 65 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 105 | 0.040 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 222 | 0.040 |
Why?
|
Astrocytes | 1 | 2019 | 58 | 0.040 |
Why?
|
Tissue Scaffolds | 1 | 2022 | 412 | 0.040 |
Why?
|
Organic Chemicals | 1 | 2019 | 7 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 511 | 0.040 |
Why?
|
Mice, Inbred C57BL | 1 | 2022 | 773 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2019 | 58 | 0.040 |
Why?
|
Models, Educational | 1 | 2019 | 20 | 0.040 |
Why?
|
Radiotherapy, Conformal | 1 | 2018 | 19 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 133 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2018 | 60 | 0.040 |
Why?
|
Injections, Spinal | 1 | 2019 | 123 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2019 | 74 | 0.040 |
Why?
|
Antigens, CD | 1 | 2019 | 105 | 0.040 |
Why?
|
Observer Variation | 1 | 2018 | 109 | 0.040 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 29 | 0.040 |
Why?
|
Patient Selection | 1 | 2020 | 289 | 0.040 |
Why?
|
Ethnic Groups | 1 | 2021 | 480 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 262 | 0.040 |
Why?
|
Genetic Testing | 1 | 2018 | 99 | 0.040 |
Why?
|
Neuronavigation | 1 | 2017 | 8 | 0.040 |
Why?
|
Disability Evaluation | 1 | 2019 | 236 | 0.040 |
Why?
|
Burnout, Professional | 1 | 2018 | 50 | 0.040 |
Why?
|
Ablation Techniques | 1 | 2017 | 26 | 0.040 |
Why?
|
Cytokines | 1 | 2019 | 262 | 0.040 |
Why?
|
Craniotomy | 1 | 2017 | 46 | 0.040 |
Why?
|
Lumbar Vertebrae | 1 | 2017 | 98 | 0.040 |
Why?
|
Neutrophils | 1 | 2017 | 118 | 0.040 |
Why?
|
Surgery, Computer-Assisted | 1 | 2017 | 56 | 0.040 |
Why?
|
Tissue Engineering | 1 | 2022 | 647 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2017 | 160 | 0.030 |
Why?
|
Child | 1 | 2022 | 2472 | 0.030 |
Why?
|
Research Design | 1 | 2017 | 313 | 0.030 |
Why?
|
Age Factors | 1 | 2018 | 1204 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 849 | 0.030 |
Why?
|
Neurosurgery | 1 | 2014 | 38 | 0.030 |
Why?
|
Emergency Medicine | 1 | 2014 | 120 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 1447 | 0.030 |
Why?
|
Sarcoidosis | 1 | 2009 | 27 | 0.020 |
Why?
|
Evoked Potentials | 1 | 2006 | 16 | 0.020 |
Why?
|
Acoustic Stimulation | 1 | 2006 | 125 | 0.020 |
Why?
|
Reaction Time | 1 | 2006 | 118 | 0.020 |
Why?
|
Photic Stimulation | 1 | 2006 | 159 | 0.020 |
Why?
|